In vivo study of a technetium labelled anti-EGFr MoAb

Francesco Scopinaro, Giuseppe De Vincentis, Maria Banci, Orazio Schillaci, Mario Di Loreto, Roberta Danieli, Maria Ierardi, Anna Maria De Paola, Walter Gianni, Rita Massa

Research output: Contribution to journalArticlepeer-review


Epithelial Growth Factor receptors (EGFr) are normally present in all the epithelial cells, but their overexpression is closely related to presence of cancer. We have raised EGF-competitive antibody against EGFr and have labelled it with 131I and technetium. The ability of this antibody to bind to A431 cells to be internalized has been tested on A431 cells cultures. Its ability to give scintigraphic images of epithelial tumors has been tested on nu/nu balb c mice xenografted with A431 cells. The labelled antibody is well internalized by cultured cells. Xenografted tumors are clearly imaged both by 131I and 99mTc anti EGFr MoAb. 99mTc labelling is very interesting. The tumor/background ratio was 0.72 ± 0.2 for 99mTc and 0.40 ± 0.6 131I labelling. Moreover very high uptake of 99mTc MoAb was obtained 2 hours after injection whereas the 131I antibody required 24 hours.

Original languageEnglish
Pages (from-to)1761-1765
Number of pages5
JournalAnticancer Research
Issue number3 B
Publication statusPublished - 1997


  • Tc labelled MoAb
  • A 431 cells
  • Anti EGFr MoAb
  • Epidermal Growth Factor Receptor (EGFr)
  • Tumor bearing balb/c n/n mouse

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'In vivo study of a technetium labelled anti-EGFr MoAb'. Together they form a unique fingerprint.

Cite this